Global Tuberculosis Drugs Market by Disease (Active TB, Latent TB), Drug Class (Combination Drugs, First-line Anti-TB Drugs, Second-line Anti-TB Drugs) - Forecast 2024-2030- Product Image

Sale

Global Tuberculosis Drugs Market by Disease (Active TB, Latent TB), Drug Class (Combination Drugs, First-line Anti-TB Drugs, Second-line Anti-TB Drugs) - Forecast 2024-2030

Report
198 Pages
March 2024
Region: Global
360iResearch™
ID: 4985928

UP TO €844EUR$875USD£724GBP OFF until Dec 31^st 2024

The Tuberculosis Drugs Market size was estimated at USD 1.92 billion in 2023, USD 2.04 billion in 2024, and is expected to grow at a CAGR of 6.28% to reach USD 2.95 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Tuberculosis Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Tuberculosis Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Tuberculosis Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., AstraZeneca PLC, Bayer AG, Bristol Myers Squibb Company, Cipla Limited, Eli Lilly and Company, F. Hoffmann-La Roche AG, Johnson & Johnson Services, Inc., Lupin Limited, Merck & Co., Inc., Novartis AG, Otsuka Pharmaceutical Co., Ltd., Pfizer, Inc., Sanofi S.A., and Takeda Pharmaceutical Company.

Market Segmentation & Coverage

This research report categorizes the Tuberculosis Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

Disease
- Active TB
- Latent TB
Drug Class
- Combination Drugs
- First-line Anti-TB Drugs
  - Ethambutol
  - Isoniazid
  - Pyrazinamide
  - Rifampin
- Second-line Anti-TB Drugs
  - Capreomycin
  - Ethionamide
  - Levofloxacin
  - Streptomycin

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report offers valuable insights on the following aspects:

Market Penetration: It presents comprehensive information on the market provided by key players.
Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

What is the market size and forecast of the Tuberculosis Drugs Market?
Which products, segments, applications, and areas should one consider investing in over the forecast period in the Tuberculosis Drugs Market?
What are the technology trends and regulatory frameworks in the Tuberculosis Drugs Market?
What is the market share of the leading vendors in the Tuberculosis Drugs Market?
Which modes and strategic moves are suitable for entering the Tuberculosis Drugs Market?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Tuberculosis Drugs Market, by Region

5. Market Insights

5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Global plan against drug-resistant TB drives diagnosis and treatment enrollment
5.1.1.2. HIV burden fuels LTBI case counts
5.1.1.3. Rising prevalence of tuberculosis
5.1.2. Restraints
5.1.2.1. High cost of MDR and XDR TB drugs
5.1.3. Opportunities
5.1.3.1. Increasing research & development of new drug development
5.1.3.2. Growing initiative from government organization for tuberculosis awareness
5.1.4. Challenges
5.1.4.1. Adverse side effects of tuberculosis drugs
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. Tuberculosis Drugs Market, by Disease

6.1. Introduction
6.2. Active TB
6.3. Latent TB

7. Tuberculosis Drugs Market, by Drug Class

7.1. Introduction
7.2. Combination Drugs
7.3. First-line Anti-TB Drugs
7.4.1. Ethambutol
7.4.2. Isoniazid
7.4.3. Pyrazinamide
7.4.4. Rifampin
7.4. Second-line Anti-TB Drugs
7.5.1. Capreomycin
7.5.2. Ethionamide
7.5.3. Levofloxacin
7.5.4. Streptomycin

8. Americas Tuberculosis Drugs Market

8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States

9. Asia-Pacific Tuberculosis Drugs Market

9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam

10. Europe, Middle East & Africa Tuberculosis Drugs Market

10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom

11. Competitive Landscape

11.1. FPNV Positioning Matrix
11.2. Market Share Analysis, By Key Player
11.3. Competitive Scenario Analysis, By Key Player

12. Competitive Portfolio

12.1. Key Company Profiles
12.1.1. AbbVie Inc.
12.1.2. AstraZeneca PLC
12.1.3. Bayer AG
12.1.4. Bristol Myers Squibb Company
12.1.5. Cipla Limited
12.1.6. Eli Lilly and Company
12.1.7. F. Hoffmann-La Roche AG
12.1.8. Johnson & Johnson Services, Inc.
12.1.9. Lupin Limited
12.1.10. Merck & Co., Inc.
12.1.11. Novartis AG
12.1.12. Otsuka Pharmaceutical Co., Ltd.
12.1.13. Pfizer, Inc.
12.1.14. Sanofi S.A.
12.1.15. Takeda Pharmaceutical Company
12.2. Key Product Portfolio

13. Appendix

13.1. Discussion Guide
13.2. License & Pricing

List of Figures

FIGURE 1. TUBERCULOSIS DRUGS MARKET RESEARCH PROCESS
FIGURE 2. TUBERCULOSIS DRUGS MARKET SIZE, 2023 VS 2030
FIGURE 3. TUBERCULOSIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. TUBERCULOSIS DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. TUBERCULOSIS DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. TUBERCULOSIS DRUGS MARKET DYNAMICS
FIGURE 7. TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2023 VS 2030 (%)
FIGURE 8. TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
FIGURE 10. TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 12. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 14. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. TUBERCULOSIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 20. TUBERCULOSIS DRUGS MARKET SHARE, BY KEY PLAYER, 2023

List of Tables

TABLE 1. TUBERCULOSIS DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. TUBERCULOSIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 6. TUBERCULOSIS DRUGS MARKET SIZE, BY ACTIVE TB, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. TUBERCULOSIS DRUGS MARKET SIZE, BY LATENT TB, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 9. TUBERCULOSIS DRUGS MARKET SIZE, BY COMBINATION DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 12. TUBERCULOSIS DRUGS MARKET SIZE, BY ETHAMBUTOL, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. TUBERCULOSIS DRUGS MARKET SIZE, BY ISONIAZID, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. TUBERCULOSIS DRUGS MARKET SIZE, BY PYRAZINAMIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. TUBERCULOSIS DRUGS MARKET SIZE, BY RIFAMPIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 18. TUBERCULOSIS DRUGS MARKET SIZE, BY CAPREOMYCIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. TUBERCULOSIS DRUGS MARKET SIZE, BY ETHIONAMIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. TUBERCULOSIS DRUGS MARKET SIZE, BY LEVOFLOXACIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. TUBERCULOSIS DRUGS MARKET SIZE, BY STREPTOMYCIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 23. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 24. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 25. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 26. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 27. ARGENTINA TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 28. ARGENTINA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 29. ARGENTINA TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 30. ARGENTINA TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 31. BRAZIL TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 32. BRAZIL TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 33. BRAZIL TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 34. BRAZIL TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 35. CANADA TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 36. CANADA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 37. CANADA TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 38. CANADA TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 39. MEXICO TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 40. MEXICO TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 41. MEXICO TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 42. MEXICO TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 43. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 44. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 45. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 48. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 49. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 50. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 51. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 52. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 53. AUSTRALIA TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 54. AUSTRALIA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 55. AUSTRALIA TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 56. AUSTRALIA TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 57. CHINA TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 58. CHINA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 59. CHINA TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 60. CHINA TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 61. INDIA TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 62. INDIA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 63. INDIA TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 64. INDIA TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 65. INDONESIA TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 66. INDONESIA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 67. INDONESIA TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 68. INDONESIA TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 69. JAPAN TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 70. JAPAN TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 71. JAPAN TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 72. JAPAN TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 73. MALAYSIA TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 74. MALAYSIA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 75. MALAYSIA TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 76. MALAYSIA TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 77. PHILIPPINES TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 78. PHILIPPINES TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 79. PHILIPPINES TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 80. PHILIPPINES TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 81. SINGAPORE TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 82. SINGAPORE TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 83. SINGAPORE TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 84. SINGAPORE TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 85. SOUTH KOREA TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 86. SOUTH KOREA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 87. SOUTH KOREA TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 88. SOUTH KOREA TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 89. TAIWAN TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 90. TAIWAN TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 91. TAIWAN TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 92. TAIWAN TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 93. THAILAND TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 94. THAILAND TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 95. THAILAND TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 96. THAILAND TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 97. VIETNAM TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 98. VIETNAM TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 99. VIETNAM TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 100. VIETNAM TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 106. DENMARK TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 107. DENMARK TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 108. DENMARK TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 109. DENMARK TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 110. EGYPT TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 111. EGYPT TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 112. EGYPT TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 113. EGYPT TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 114. FINLAND TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 115. FINLAND TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 116. FINLAND TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 117. FINLAND TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 118. FRANCE TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 119. FRANCE TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 120. FRANCE TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 121. FRANCE TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 122. GERMANY TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 123. GERMANY TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 124. GERMANY TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 125. GERMANY TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 126. ISRAEL TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 127. ISRAEL TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 128. ISRAEL TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 129. ISRAEL TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 130. ITALY TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 131. ITALY TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 132. ITALY TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 133. ITALY TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 134. NETHERLANDS TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 135. NETHERLANDS TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 136. NETHERLANDS TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 137. NETHERLANDS TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 138. NIGERIA TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 139. NIGERIA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 140. NIGERIA TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 141. NIGERIA TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 142. NORWAY TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 143. NORWAY TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 144. NORWAY TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 145. NORWAY TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 146. POLAND TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 147. POLAND TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 148. POLAND TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 149. POLAND TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 150. QATAR TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 151. QATAR TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 152. QATAR TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 153. QATAR TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 154. RUSSIA TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 155. RUSSIA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 156. RUSSIA TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 157. RUSSIA TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 158. SAUDI ARABIA TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 159. SAUDI ARABIA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 160. SAUDI ARABIA TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 161. SAUDI ARABIA TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 162. SOUTH AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 163. SOUTH AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 164. SOUTH AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 165. SOUTH AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 166. SPAIN TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 167. SPAIN TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 168. SPAIN TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 169. SPAIN TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 170. SWEDEN TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 171. SWEDEN TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 172. SWEDEN TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 173. SWEDEN TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 174. SWITZERLAND TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 175. SWITZERLAND TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 176. SWITZERLAND TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 177. SWITZERLAND TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 178. TURKEY TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 179. TURKEY TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 180. TURKEY TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 181. TURKEY TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 182. UNITED ARAB EMIRATES TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 183. UNITED ARAB EMIRATES TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 184. UNITED ARAB EMIRATES TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 185. UNITED ARAB EMIRATES TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 186. UNITED KINGDOM TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 187. UNITED KINGDOM TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 188. UNITED KINGDOM TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 189. UNITED KINGDOM TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 190. TUBERCULOSIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
TABLE 191. TUBERCULOSIS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 192. TUBERCULOSIS DRUGS MARKET LICENSE & PRICING

Companies Mentioned

AbbVie Inc.
AstraZeneca PLC
Bayer AG
Bristol Myers Squibb Company
Cipla Limited
Eli Lilly and Company
F. Hoffmann-La Roche AG
Johnson & Johnson Services, Inc.
Lupin Limited
Merck & Co., Inc.
Novartis AG
Otsuka Pharmaceutical Co., Ltd.
Pfizer, Inc.
Sanofi S.A.
Takeda Pharmaceutical Company

Methodology

LOADING...

Table Information

Report Attribute	Details
No. of Pages	198
Published	March 2024
Forecast Period	2024 - 2030
Estimated Market Value ( USD ) in 2024	$ 2.04 Billion
Forecasted Market Value ( USD ) by 2030	$ 2.95 Billion
Compound Annual Growth Rate	6.2%
Regions Covered	Global
No. of Companies Mentioned	15

PURCHASE OPTIONS

Single User License Online Access - 1 Year

Single User License PDF, Excel And Online Access - 1 Year

1 - 5 User License PDF, Excel And Online Access - 1 Year

Site License PDF, Excel And Online Access - 1 Year

Enterprise License PDF, Excel And Online Access - 1 Year

need a quote ?

License	Format	Properties	Price
SINGLE USER LICENSE Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a single user license, allowing one user access to the product.	€3257EUR$3,374USD£2,794GBP €3619EUR$3,749USD£3,104GBP
SINGLE USER LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a single user license, allowing one user access to the product.	€4125EUR$4,274USD£3,539GBP €4584EUR$4,749USD£3,932GBP
1 - 5 USER LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a 1-5 user license, allowing up to five users have access to the product.	€4994EUR$5,174USD£4,284GBP €5549EUR$5,749USD£4,760GBP
SITE LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€5863EUR$6,074USD£5,029GBP €6514EUR$6,749USD£5,588GBP
ENTERPRISE LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is an enterprise license, allowing all employees within your organization access to the product.	€7600EUR$7,874USD£6,519GBP €8445EUR$8,749USD£7,244GBP

FPNV Positioning Matrix

Market Share Analysis

Key Company Profiles

Market Segmentation & Coverage

The report offers valuable insights on the following aspects:

The report addresses key questions such as:

Table of Contents

Companies Mentioned

Methodology

Table Information

Related Topics

Related Reports

Anti Tuberculosis Therapeutics Market Report and Forecast 2024-2032

Anti-Tuberculosis Therapeutics Market by Disease Type, Diagnosis and Treatment, End User, and Region 2023-2028

Anti-Tuberculosis Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028

Tuberculosis Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F Segmented By Disease Type, By Therapy, By Route of Administration, By Dosage Form, By Distribution Channel, By Region and Competition

Tuberculosis Therapeutics: Global Strategic Business Report

About the Tuberculosis Drug Market